Bendamustine

CHEMBL487253 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

358.3 g/mol

LogP

2.9

Phase

4

A chemotherapy agent with dual alkylating and antimetabolite properties that cross-links and breaks DNA strands in cancer cells, triggering cell death. It is used in lymphomas, chronic lymphocytic leukemia, and multiple myeloma.

Moleküler Ağırlık

358,3000 g/mol

LogP

2,90

TPSA

58,40 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Etki Mekanizması

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21

InChI

InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)

Molecular Formula

C16H21Cl2N3O2

HBD / HBA

1 / 4

Döndürülebilir Bağlar

9

Ağır Atomlar

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A chemotherapy agent with dual alkylating and antimetabolite properties that cross-links and breaks DNA strands in cancer cells, triggering cell death. It is used in lymphomas, chronic lymphocytic leukemia, and multiple myeloma.

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Yes, Bendamustine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL487253. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 65628. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Bendamustine PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H21Cl2N3O2
Eş Anlamlılar: 4

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.